Glucagon‐like peptide‐1 receptor agonist regulates fat browning by altering the gut microbiota and ceramide metabolism
Abstract Studies have shown that antidiabetic drugs can alter the gut microbiota. The hypoglycemic effects of the drugs can be attributed in part to certain species in the gut microbiome that help the drugs work more effectively. In addition, increasing energy expenditure via the induction of adipos...
Main Authors: | Ke Lin, Chunyan Dong, Binyan Zhao, Bailing Zhou, Li Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-12-01
|
Series: | MedComm |
Subjects: | |
Online Access: | https://doi.org/10.1002/mco2.416 |
Similar Items
-
Glucagon-like peptide-1 receptor agonists in neoplastic diseases
by: Lisan Ji, et al.
Published: (2024-09-01) -
Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
by: A. Delgado, et al.
Published: (2021-04-01) -
A Changed Gut Microbiota Diversity Is Associated With Metabolic Improvements After Duodenal Mucosal Resurfacing With Glucagon-Like-Peptide-1 Receptor Agonist in Type 2 Diabetes in a Pilot Study
by: Suzanne Meiring, et al.
Published: (2022-07-01) -
Hepatic function of glucagon-like peptide-1 and its based diabetes drugs
by: Feng Jia Nuo, et al.
Published: (2024-08-01) -
Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review
by: Teshome G, et al.
Published: (2020-09-01)